Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2023

29.10.2022 | Original Article

The feasibility of ultra-early and fast total‑body [68 Ga]Ga-FAPI-04 PET/CT scan

verfasst von: Ruohua Chen, Xinlan Yang, Xiaofeng Yu, Xiang Zhou, Yee Ling Ng, Yumei Chen, Lianghua Li, Yun Zhou, Gang Huang, Jianjun Liu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[68 Ga]Ga-FAPI-04 PET/CT has been widely used in oncology patients. The patients need to lie still for 20–30 min during scan after waiting for 60 min post-tracer injection in traditional [68 Ga]Ga-FAPI-04 PET/CT scan. This is difficult for some patients who are intolerant to prolonged horizontal positioning and waiting time. Therefore, we evaluated the diagnostic value of the images obtained in ultra-early and fast scan (5-min p.i., 30-s acquisition time) by the total-body [68 Ga]Ga-FAPI-04 PET/CT and to investigate whether they could meet the requirements of clinical diagnosis.

Methods

Total-body [68 Ga]Ga-FAPI-04 PET/CT was conducted in 12 patients at the Renji Hospital. Patients underwent PET with two acquisitions: 5-min p.i. and 30-s acquisition time (ultra-early and fast imaging) and 60-min p.i. and 300-s acquisition time (traditional imaging). Mean [68 Ga]Ga-FAPI-04 injection dose was 1.85 MBq/kg.

Results

Forty-four lesions were detected in 12 patients on traditional imaging. All the 44 lesions on conventional imaging could also detected by ultra-early and fast imaging. For all the 12 patients, the tumor stage did not change, as same lesions were visible for every case in both images. There was no statistically significant difference in SUVmax of lesions between ultra-early and fast imaging and traditional imaging (12.5 ± 8.7 vs 13.7 ± 8.5, P = 0.528). Background bloodpool (4.0 ± 0.6 vs 0.9 ± 0.2, P < 0.001)and liver (2.5 ± 0.7 vs 1.0 ± 0.5, P < 0.001)at traditional imaging showed a significant decrease in SUVmean compared to ultra-early and fast imaging.

Conclusions

Ultra-early and fast imaging versus traditional [68 Ga]Ga-FAPI-04 imaging resulted in equivalent tumor detection and lesion uptake. Ultra-early and fast total-body [68 Ga]Ga-FAPI-04 PET/CT scan could meet clinical diagnostic requirements for patients with poor tolerant to prolonged horizontal positioning and waiting time.
Literatur
1.
Zurück zum Zitat Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.CrossRef Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.CrossRef
2.
Zurück zum Zitat Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.CrossRef Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.CrossRef
3.
Zurück zum Zitat Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [(18)F]F-FDG in oncology: a systematic review. Int J Mol Sci 2021;22 Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [(18)F]F-FDG in oncology: a systematic review. Int J Mol Sci 2021;22
4.
Zurück zum Zitat Kuten J, Levine C, Shamni O, et al. Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2022;49:743–50.CrossRef Kuten J, Levine C, Shamni O, et al. Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2022;49:743–50.CrossRef
5.
Zurück zum Zitat Giesel FL, Kratochwil C, Schlittenhardt J, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:4377–85.CrossRef Giesel FL, Kratochwil C, Schlittenhardt J, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:4377–85.CrossRef
6.
Zurück zum Zitat Qin C, Liu F, Huang J, et al. A head-to-head comparison of (68)Ga-DOTA-FAPI-04 and (18)F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48:3228–37.CrossRef Qin C, Liu F, Huang J, et al. A head-to-head comparison of (68)Ga-DOTA-FAPI-04 and (18)F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48:3228–37.CrossRef
7.
Zurück zum Zitat Pang Y, Zhao L, Luo Z, et al. Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393–402.CrossRef Pang Y, Zhao L, Luo Z, et al. Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393–402.CrossRef
8.
Zurück zum Zitat Zhao L, Pang Y, Zheng H, et al. Clinical utility of [(68)Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3606–17.CrossRef Zhao L, Pang Y, Zheng H, et al. Clinical utility of [(68)Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3606–17.CrossRef
9.
Zurück zum Zitat Qin C, Shao F, Gai Y, et al. (68)Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET/CT. J Nucl Med. 2022;63:81–8.CrossRef Qin C, Shao F, Gai Y, et al. (68)Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET/CT. J Nucl Med. 2022;63:81–8.CrossRef
10.
Zurück zum Zitat Shi X, Xing H, Yang X, et al. Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593–603.CrossRef Shi X, Xing H, Yang X, et al. Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593–603.CrossRef
11.
Zurück zum Zitat Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60:299–303.CrossRef Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60:299–303.CrossRef
12.
Zurück zum Zitat Zhang X, Zhou J, Cherry SR, Badawi RD, Qi J. Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scanner. Phys Med Biol. 2017;62:2465–85.CrossRef Zhang X, Zhou J, Cherry SR, Badawi RD, Qi J. Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scanner. Phys Med Biol. 2017;62:2465–85.CrossRef
13.
Zurück zum Zitat Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91.CrossRef Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91.CrossRef
14.
Zurück zum Zitat Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R. Determination of optimal (68) Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT. Eur J Nucl Med Mol Imaging. 2022;49:2086–95.CrossRef Wen J, Zhu Y, Li L, Liu J, Chen Y, Chen R. Determination of optimal (68) Ga-PSMA PET/CT imaging time in prostate cancers by total-body dynamic PET/CT. Eur J Nucl Med Mol Imaging. 2022;49:2086–95.CrossRef
15.
Zurück zum Zitat Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117:2265–7.CrossRef Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117:2265–7.CrossRef
16.
Zurück zum Zitat Zhang YQ, Hu PC, Wu RZ, et al. The image quality, lesion detectability, and acquisition time of (18)F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020;47:2507–15.CrossRef Zhang YQ, Hu PC, Wu RZ, et al. The image quality, lesion detectability, and acquisition time of (18)F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020;47:2507–15.CrossRef
17.
Zurück zum Zitat Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171–7.CrossRef Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171–7.CrossRef
Metadaten
Titel
The feasibility of ultra-early and fast total‑body [68 Ga]Ga-FAPI-04 PET/CT scan
verfasst von
Ruohua Chen
Xinlan Yang
Xiaofeng Yu
Xiang Zhou
Yee Ling Ng
Yumei Chen
Lianghua Li
Yun Zhou
Gang Huang
Jianjun Liu
Publikationsdatum
29.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-06004-3

Weitere Artikel der Ausgabe 3/2023

European Journal of Nuclear Medicine and Molecular Imaging 3/2023 Zur Ausgabe